Scinvivo, an Eindhoven-based medtech startup, has successfully raised €4.7M in funding to enhance its innovative cancer diagnostics technology. The investment round was led by Santec OIS Corporation and The NLC Health Impact fund, with additional support from current shareholders and an “Innovatiekrediet” (Innovation credit) loan from the Netherlands Enterprise Agency (RvO).
The funding will be utilized to improve Scinvivo’s catheter, OCT (Optical Coherence Tomography) system, and software, making it more appealing and usable for urologists in clinical settings. Marijn van Os, CEO and co-founder of Scinvivo, expressed enthusiasm about the investment, highlighting the strengthened supply chain and market foothold in Japan through Santec, as well as the support from NLC’s Health Impact Fund, Europe’s largest investor in medical startups.
Advertisement
Preparing for Clinical Trials and CE Certification
Scinvivo plans to conduct clinical trials to demonstrate the clinical benefits of its product and prepare the necessary documentation for obtaining CE certification. CMO Maaike de Jong looks forward to collaborating with Santec and achieving the first in vivo clinical results, bringing the OCT imaging platform closer to market introduction.
Revolutionizing Cancer Diagnostics
Led by Marijn van Os, Scinvivo aims to improve cancer diagnostics for better patient outcomes by reducing unnecessary surgeries and increasing diagnostic accuracy. The company is developing an imaging platform based on a forward-looking OCT catheter to visualize human morphological tissue structure with high resolution, filling a gap in current imaging modalities and enabling more precise invasive surgeries.
Investor Confidence in the Company’s Vision
Santec, guided by a commitment to optical technology, and NLC Health Ventures, the world’s largest venture builder in healthtech, have shown strong support for Scinvivo’s mission. Changho Chong, CTO of Santec, believes that cancer screening with Scinvivo’s OCT technology will set a new milestone in bladder cancer procedures and other endoscopy applications.
With this funding, the company is poised to make significant advancements in cancer diagnostics, offering a precise, personalized treatment approach that could greatly improve patient outcomes and revolutionize the field.
